C. Rordorf

发表

Effect of Rifampin on Apparent Clearance of Everolimus

J. Kovarik, Stefan Hartmann, Joaquim Figueiredo, 2002, The Annals of pharmacotherapy.

Assessment of Lumiracoxib Bioavailability from Targeted Sites in the Human Intestine Using Remotely Activated Capsules and Gamma Scintigraphy

I. Wilding, A. Connor, C. Rordorf, 2004, Pharmaceutical Research.

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)

A. Chakraborty, J. Roesler, C. Rordorf, 2011, Arthritis Research & Therapy.

Pharmacokinetic and Pharmacodynamic Assessments of HMG‐CoA Reductase Inhibitors When Coadministered with Everolimus

J. Kovarik, Stefan Hartmann, C. Rordorf, 2002, Journal of clinical pharmacology.

Population pharmacokinetics of everolimus in de novo renal transplant patients: Impact of ethnicity and comedications

J. Kovarik, C. Rordorf, Chyi-Hung Hsu, 2001, Clinical pharmacology and therapeutics.

The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

L. Joosten, P. V. van Riel, G. Burmester, 2008, Arthritis research & therapy.

The PKC inhibitor AEB071 may be a therapeutic option for psoriasis.

B. Wolff, M. Dawid, O. Grenet, 2008, The Journal of clinical investigation.

Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment

J. Kovarik, K. Lasseter, C. Reynolds, 2001, Clinical pharmacology and therapeutics.

Differential Influence of Two Cyclosporine Formulations on Everolimus Pharmacokinetics: A Clinically Relevant Pharmacokinetic Interaction

J. Kovarik, Joaquim Figueiredo, M. Rouilly, 2002, Journal of clinical pharmacology.

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post‐transplant year: Pharmacokinetics, exposure‐response relationships, and influence on cyclosporine

J. Kovarik, B. Kaplan, M. Rouilly, 2001, Clinical pharmacology and therapeutics.

Effect of Food on Everolimus Absorption: Quantification in Healthy Subjects and a Confirmatory Screening in Patients with Renal Transplants

J. Kovarik, H. Neumayer, G. Golor, 2002, Pharmacotherapy.

Influence of Delayed Initiation of Cyclosporine on Everolimus Pharmacokinetics in de Novo Renal Transplant Patients

J. Kovarik, J. Dantal, M. Rouilly, 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Gastroduodenal tolerability of lumiracoxib vs. placebo and naproxen: a pilot endoscopic study in healthy male subjects

C. Rordorf, J. Branson, S. Milosavljev, 2003, Alimentary pharmacology & therapeutics.

Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range.

J. Kovarik, B. Kaplan, J. Dantal, 2002, Transplantation.

Clinical Development of an Everolimus Pediatric Formulation: Relative Bioavailability, Food Effect, and Steady‐State Pharmacokinetics

J. Kovarik, C. Rordorf, A. Noè, 2003, Journal of clinical pharmacology.

Concomitant Administration of Lumiracoxib and a Triphasic Oral Contraceptive Does Not Affect Contraceptive Activity or Pharmacokinetic Profile

C. Rordorf, S. Milosavljev, G. Scott, 2004, Journal of clinical pharmacology.

No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor.

K. Lasseter, C. Rordorf, S. Milosavljev, 2004, Pharmacological research.

Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody

H. Gram, A. Chakraborty, S. Tannenbaum, 2012, Clinical Pharmacokinetics.

Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects.

C. Rordorf, J. Mangold, L. Rodriguez, 2004, Drug metabolism and disposition: the biological fate of chemicals.

In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes

Helen J. Lachmann, Philip N. Hawkins, P. Hawkins, 2009, The Journal of experimental medicine.

Lumiracoxib Does Not Affect Methotrexate Pharmacokinetics in Rheumatoid Arthritis Patients

P. Lafforgue, Stefan Hartmann, C. Rordorf, 2004, The Annals of pharmacotherapy.

Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure.

J. Kovarik, D. Mancini, H. Eisen, 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Pharmacokinetics of an Everolimus‐Cyclosporine Immunosuppressive Regimen Over the First 6 Months After Kidney Transplantation

J. Kovarik, B. Kaplan, J. Dantal, 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study.

C. Hawkey, C. Rordorf, J. Branson, 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Pharmacokinetics of Lumiracoxib in Plasma and Synovial Fluid

C. Reynolds, C. Rordorf, S. Milosavljev, 2004, Clinical pharmacokinetics.

Lumiracoxib Does Not Affect the Ex Vivo Antiplatelet Aggregation Activity of Low‐Dose Aspirin in Healthy Subjects

R. Schmouder, M. Guillaume, C. Rordorf, 2005, Journal of clinical pharmacology.

Clinical Pharmacology of Lumiracoxib

C. Rordorf, J. Mangold, P. Marshall, 2005, Clinical pharmacokinetics.

Lumiracoxib: Pharmacokinetic and Pharmacodynamic Profile When Coadministered with Fluconazole in Healthy Subjects

C. Rordorf, S. Milosavljev, G. Scott, 2004, Journal of clinical pharmacology.

Lack of Effect of Omeprazole or of an Aluminium Hydroxide/Magnesium Hydroxide Antacid on the Pharmacokinetics of Lumiracoxib

C. Reynolds, C. Rordorf, M. Shenouda, 2004, Clinical pharmacokinetics.

The PKC inhibitor AEB071 may be a therapeutic option for psoriasis.

B. Wolff, M. Dawid, O. Grenet, 2008, The Journal of clinical investigation.

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)

N. Wulffraat, P. Woo, B. Bader-Meunier, 2008, Pediatric Rheumatology Online Journal.